AirNexis Therapeutics
AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment
AirNexis Therapeutics Launches with $200M Series A
AirNexis Therapeutics has emerged from stealth with $200 million in Series A financing to advance a novel therapy for chronic obstructive pulmonary disease (COPD).
The round was led by Frazier Life Sciences with participation from OrbiMed, SR One, Goldman Sachs, Longitude Capital, and Enavate Sciences.
Key Highlights
- One of the largest Series A rounds in biotech
- Novel dual PDE3/4 inhibitor for COPD
- Combines bronchodilation and inflammation reduction
Company Overview
AirNexis Therapeutics is developing a dual PDE3/4 inhibitor that combines bronchodilation with anti-inflammatory effects, potentially offering COPD patients a more effective treatment option.
Company Info
Investors (4)
Share
Related Reports
Armadin Raises $255.5M Series B for Autonomous Security
Armadin raised a $255.5 million Series B co-led by Andreessen Horowitz and Accel to scale its agentic security platform and its research, training, and go-to-market efforts.
Homeward Raises $120M Series D for Cash Offer and Bridge Financing
Homeward raised a $120 million Series D led by Saluda Grade, plus $330 million in asset-backed debt, to expand cash offer and bridge financing for real estate agents.
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free